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SubcutaneousThe safe and efﬁcacious delivery of membrane impermeable therapeutics requires cytoplasmic access without
the toxicity of nonspeciﬁc cytoplasmicmembrane lysis. We have developed amechanism for control of cytoplas-
mic releasewhich utilizes endogenous proteases as a trigger and results in functional delivery of small interfering
RNA (siRNA). The delivery approach is based on reversible inhibition of membrane disruptive polymers with
protease-sensitive substrates. Proteolytic hydrolysis upon endocytosis restores the membrane destabilizing ac-
tivity of the polymers thereby allowing cytoplasmic access of the co-delivered siRNA. Protease-sensitive polymer
masking reagents derived from polyethylene glycol (PEG), which inhibit membrane interactions, and N-
acetylgalactosamine, which targets asialoglycoprotein receptors on hepatocytes, were synthesized and used to
formulatemasked polymer-siRNAdelivery vehicles. The size, charge and stability of the vehicles enable function-
al delivery of siRNA after subcutaneous administration and, with modiﬁcation of the targeting ligand, have the
potential for extrahepatic targeting.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Competing attributes must be included in the design of any system-
ically administered, selectively-targeted delivery vehicle for membrane
impermeable therapeutics: interactions with membranes that facilitate
cytoplasmic delivery and an absence of interactions with membranes,
which is necessary for cell targeting and safety. Membrane perturbation
is required in order to facilitate the transit of membrane impermeable
material such as siRNA into the cytoplasm of the cell. However,
uncontrolled, non-speciﬁc membrane interactions reduce circulation,
preclude cell targeting, and are inherently cytotoxic. Due to these non-
speciﬁc interactions, it is necessary to control the membrane
permeabilizing ability of delivery vehicles such that membrane pertur-
bation occurs only at the desired location. The incorporation of a
physiologically-sensitive triggering mechanism to switch between
membrane disruptive andmembrane inert states is necessary for a suc-
cessful delivery vehicle.
Acid-labile functional groups, which rely upon the pH gradient
present in the endosome/lysosome pathway, have been incorporated
as triggers to regulate the membrane lytic activity of delivery vehicles.
Labile bonds such as acetals [1–3], hydrazone [4], ortho esters [5–8],
vinyl ethers [9] and maleamates [10–12] have been incorporated intoema).
. This is an open access article underliposomes and amphipathic polymers to control interactions with
membranes and provide a trigger for cytoplasmic delivery.
In addition to the pH gradient that exists in the endosome/lysosome
pathway, the increase in hydrolytic enzymes, nucleases, esterases and
proteases has also been harnessed to great utility in the targeted
delivery of small molecule prodrugs [13]. The use of enzymatic triggers
is attractive in that the hydrolyzed bonds (e.g. amides, esters,
phosphodiesters) are relatively easily synthesized and stable in the
absence of degrading enzymes. Despite the attractiveness of enzyme-
based triggering mechanisms there is a paucity of examples using lyso-
somal enzymes to trigger the release of macromolecular therapeutics.
The most obvious reason for this lack of hydrolase-triggered delivery is
the fact that the macromolecular therapeutic (either protein or
polynucleic acid) is itself a substrate for hydrolysis, and as a consequence
hydrolase-triggered cytoplasmic release of these agents is in competition
with the degradation of the therapeutic itself. The advent of nuclease-
resistant oligonucleotides as therapeutic agents has provided an
opportunity for the design of nucleic acid delivery vehicles that rely on
hydrolytic enzymes for triggered cytoplasmic release of nucleic acids.
Presented herein is the development of protease-sensitive delivery
vehicles for siRNA. These delivery vehicles expand on the pH-sensitive
dynamic polyconjugates (DPCs) previously described [14]. The pH-
sensitive DPCs utilized a maleic anhydride for reversible masking of
the membrane-interactive polyamine. The maleic anhydride and
amine form amaleamate that is stable under basic conditions, but revertthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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under acidic physiological conditions. The more stable protease-sensitive
linkages survive longer in circulation, and allow an increased range of
targeting using the same polymers as those developed for pH-sensitive
DPCs.
2. Materials and methods
2.1. Materials
2,2′-Azobis(2-methylpropionitrile) (AIBN, radical initiator), 2-(2-
aminoethoxy) ethanol, BOC anhydride, acryloyl chloride and 4-Cyano-
4-(phenylcarbonothioylthio) pentanoic acid (CPCPA, RAFT Agent)
were purchased from Sigma Aldrich. Sec-butyl acrylate monomer was
obtained from Polysciences Inc. 12 units PEGylation reagent (m-
dPEG12-NHS) was purchased from Quanta Biodesign.
2.1.1. siRNAs
The siRNAs of the following sequences were synthesized using stan-
dard phosphoramidite chemistry.
siF7 sense: 5′-(NH2–C6)-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf (invdT)
siF7 antisense: 5′dT*GfaGfuUfgGfcAfcGfcCfuUfuGfcdT*dT-3′
siLuc sense: 5′-(NH2–C6)-cuuAcGcuGAGuAcuucGAdT*dT-3′; and
siLuc antisense: 5′-UCGAAGuACUcAGCGuAAGdT*dT-3′.
(lower case, 2′-OMe substitution; f, 2′-F substitution; d, 2-deoxy
substitution; and *, phosphorothioate linkage.)
2.2. Modiﬁcations of amine siRNA with acetyl-protected thiol group
SATA-modiﬁed siRNAs were synthesized by reaction of 5′ amine-
modiﬁed siRNA with 1 weight equivalents (wt. eq.) of N-succinimidyl-
S-acetylthioacetate (SATA) reagent (Pierce) and 0.36 wt. eq. of
NaHCO3 in water at 4 °C for 16 h. The modiﬁed siRNAs were then
precipitated by the addition of 9 volumes of ethanol and incubation at
−80 °C for 2 h. The precipitate was dissolved in RNase-free PBS buffer
and quantiﬁed by measuring absorbance at the 260 nm.
2.3. N-Boc-ethoxyethylamine acrylate
In a 2L round-bottom ﬂask equipped with a stir bar, 2-(2-
aminoethoxy) ethanol (21.1 g, 202.9 mmol, Sigma Aldrich) was dis-
solved in 350 mL dichloromethane. In a separate 1L ﬂask, BOC anhy-
dride (36.6 g, 169.1 mmol) was dissolved in 660 mL dichloromethane.
The 2L round-bottom ﬂask was ﬁtted with an addition funnel and BOC
anhydride solution was added to the ﬂask over 6 h. The reaction was
left to stir overnight. In a 2L separatory funnel, the product was washed
with 300 mL each of 10% citric acid, 10% K2CO3, sat. NaHCO3, and sat.
NaCl. The product, BOC protected 2-(2-aminoethoxy) ethanol, was
dried over Na2SO4, gravity ﬁltered, andDCMwas evaporated using rota-
ry evaporation and high vacuum.Fig. 1. The common amine product of pH-labile maIn a 500mL round bottom ﬂask equipped with a stir bar and ﬂushed
with argon, BOC protected 2-(2-aminoethoxy) ethanol (27.836 g,
135.8 mmol) was added, followed by 240mL anhydrous dichlorometh-
ane. Diisopropylethyl amine (35.5 mL, 203.7 mmol) was added, and the
systemwas placed in a dry ice/acetone bath. Acryloyl chloride (12.1mL,
149.4 mmol) was diluted using 10 mL of dichloromethane, and added
drop-wise to the argon ﬂushed system. The system was kept under
argon and left to come to room temperature and stirred overnight.
The product was washed with 100 mL each of dH2O, 10% citric acid,
10% K2CO3, sat. NaHCO3, and saturated NaCl. The product, BOC-amino
ethyl ethoxy acrylate (BAEEA), was dried over Na2SO4, gravity ﬁltered,
and DCM was evaporated using rotary evaporation. The product was
puriﬁed through column chromatography on 29 cm of silica using a
7.5 cmdiameter column. The solvent systemusedwas 30% ethyl acetate
in hexane. Rf: 0.30. Fractions were collected and solvent was removed
using rotary evaporation andhigh vacuum. Boc-ethoxyethylamine acry-
late was obtained with 74% yield and was stored in the freezer.2.4. RAFT copolymer of N-Boc-ethoxyethylamine acrylate and sec-butyl
acrylate (EAB)
Solutions of AIBN (1.00mg/mL) and RAFT agent CPCPA (10.0mg/mL)
in butyl acetate were prepared. Monomer molar feed was 55% N-Boc-
ethoxyethylamine acrylate, 45% sec-butyl acrylate (CAS # 2998-08-5).
Theoretical Mw was 100,000.
N-Boc-ethoxyethylamine acrylate (0.890 g, 3.43mmol) sec-butyl ac-
rylate (0.391 mL, 0.360 g, 2.81 mmol) CPCPA solution (0.350 mL,
0.0125mmol), AIBN solution (0.308mL, 0.00188mmol), and butyl ace-
tate (5.3 mL) were added to a 20 mL glass vial with a stir bar. The vial
was sealed with a septa cap and the solution bubbled with nitrogen
using a long syringe with a second syringe as the outlet for 1 h. The sy-
ringes were removed and the vial heated to 80 °C for 16 h using an oil
bath. The solution was allowed to cool to room temperature and trans-
ferred to a 50 mL centrifuge tube before hexane (35 mL) was added to
the solution. The solution was centrifuged for 2 min at 4400 rpm. The
supernatant layer was carefully decanted and the bottom (solid or gel-
like) layer was rinsed with hexane. The bottom layer was then re-
dissolved in DCM (7 mL), precipitated in hexane (40 mL) and centri-
fuged once more. The supernatant was decanted and the bottom layer
rinsed with hexane before the polymer was dried under reduced pres-
sure for several hours. The yield of crude EAB copolymer was 0.856 g.
Samples of the crude polymer were taken for multi-angle light scatter-
ing (MALS). The dried, crude copolymer was dissolved in DCM
(100 mg/mL). Hexane was added until just after the cloud point was
reached. The resulting milky solution was centrifuged. The bottom
layer was extracted and fully precipitated into hexane. The fraction
was centrifuged, after which the copolymer was isolated and dried
under vacuum. The yield of isolated fraction of EAB copolymer was
0.478 g. Samples of the fractionated copolymer were taken for 1H-
NMR and MALS. The composition determined by 1H-NMR was 61% N-
Boc-ethoxyethylamine and acrylate, 39% sec-butyl acrylate.leamate and protease cleavable amide bonds.
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Approximately 10mg of the copolymer was dissolved in 0.5 mL 75%
dichloromethane, 20% tetrahydrofuran, and 5% acetonitrile. The molec-
ular weight and polydispersity (PDI) were measured using a Wyatt
Heleos II multiangle light scattering detector attached to a Shimadzu
Prominence HPLC using a Jordi 5 μ 7.8 × 300Mixed Bed LS DVB column.
Crude Polymer: MW: 59,000 (PDI 1.3), Fractionated Polymer: MW
70,000 (PDI:1.1).2.6. Deprotection/dialysis
The dried samples were treated with 2 M HCl in acetic acid (~7 mL)
for 1 h to remove the BOC protecting groups. Then the reaction was di-
luted with 20 mL of water and allowed to stir for 10–15 min. The frac-
tions were then dialyzed with 3500 MW dialysis tubing in high salt,
and water for 15 h, 8 h, and 15 h respectively. The fractions were then
transferred to 50 mL centrifuge tubes and lyophilized for 3 days or
until dry. The dry samples were brought up at 20 mg/mL in water for
further study.2.7. Small molecule syntheses
Protease masking groups PEG-FCit-PABC, PEG-fcit PABC, NAG-ACit
PABC and NAG-acit PABC were synthesized using standard amide cou-
pling reagents. See supplemental data for synthetic details.2.8. Hemolysis
Lysis of rat red blood cells (RBCs) was assessed by hemoglobin re-
lease assay. RBCs (1 mL) were diluted into 1× PBS (Corning cellgro)
and rinsed 5 times by centrifugation (5 min at 2000 rpm). The rinsed
cells were further diluted to give a 2% ﬁnal concentration RBC solution.
To each well (96 well NUNC round bottom plate) 75 μL of 1× PBS was
added, to the ﬁrst well an additional 63 μL of PBS was added as well as
12 μL of modiﬁed polymer (5 mg/mL) and serial dilutions were per-
formed, discarding the last 75 μL. The assay plate was incubated at
room temperature for 1 h. After 1 h incubation, the plate was centri-
fuged at 1000 rpm for 5 min and supernatant (25 μL) from each well
was diluted within PBS buffer (175 μL) in a 96 well ﬂat-bottomed
plate (NUNC). Hemolysis was monitored by measuring the absorbance
of the release hemoglobin at 405 nm using a plate reader (TECAN
inﬁnite M1000 Pro). Hemolysis was determined relative to the positive
lysis control Triton X-100 (10% v/v in water) and the negative control
buffer. The percentage of hemolysis was calculated as: 1− ((Absorbance
sample − Absorbance negative control) / (Absorbance of positive
control− Absorbance negative control)). HC25 was deﬁned as the poly-
mer concentration causing 25% hemolysis. The experiments were done
in triplicate.2.9. TNBS assay
2,4,6 trinitrobenzene sulfonic acid (TNBS, Eastman Kodak) was dis-
solved in water at 2 mg/mL. To each well (96 well ﬂat-bottom plate
NUNC) was added 190 μL of 50 mM BORAX pH 9 (sodium tetraborate
decahydrate, Aldrich) and 8 μL of TNBS (2mg/mL). Unmodiﬁed polymer
at 2 mg/mL was added to give the desired standard curve (0–12 μg).
10 μg of modiﬁed polymer was added and incubated at room tempera-
ture for 20 min. Absorbance was measured at 420 nm using TECAN (in-
ﬁnite M100Pro). % modiﬁcation values were calculated from the
unmodiﬁed polymer standard curve. Experiments were performed in
triplicate.2.10. siRNA-polymer formulations
Polyacrylate EAB in 5mMpH8.0 HEPES bufferwasmodiﬁed 1.5wt.%
with the activated disulﬁde reagent succinimidyloxycarbonyl-alpha-
methyl-alpha(2-pyridyl-dithio)toluene (SMPT) (Pierce) to provide
thiol reactive groups for subsequent attachment of siRNA. The thiol-
reactive polymer was then diluted to 5 mg/mL in 60 mg/mL HEPES
base. To this solution was added 10 mg/mL various protease-cleavable
PEG masking reagents. This amount of amine-reactive PEG reagents is
0.25 molar equivalents to polymer amine groups. After 1 h, acetyl-
protected thiol endogenous rodent or primate factor VII siRNA (0.1 to
0.2 wt. eq relative to polymer) was added to the polymer solution.
After incubation overnight, conjugates were further modiﬁed by the ad-
dition of an N-acetylgalactosamine derivative CDM-NAG (presented in
Fig. 6) or NAG-ACit-PABC (presented in Figs. 7–9), which was added to
30mg/mL (2mol eq per amine for CDM-NAG and 1mol eq per polymer
amine for PABC reagents) and incubated for 30 min.
2.11. Mice and injection procedures
Female ICR mice, 6 to 8 weeks old, were obtained from Harlan
Sprague–Dawley, (Indianapolis, IN). All themicewere handled in accor-
dancewith animal used protocols approved by the Animal Care and Use
Committee at ArrowheadMadison Inc. Mice were maintained on a 12 h
light/dark cycle with free access to water and food (Harlan Teklad Ro-
dent Diet, Harlan, Madison, WI). For mouse injections, modiﬁed poly-
mer and siRNA were mixed together in delivery solution and injected
as a bolus into the tail vein in a total volume of 0.2 mL of HEPES-
buffered (5 mM, pH 7.5) isotonic glucose under standard conditions.
For the subcutaneous injections, an area of loose skin on the back is tent-
ed and a needle (22 to 25 gauge) is inserted just under the skin in the
dorsal aspect of the neck with similar formulation conditions.
2.12. Confocal imaging of ﬂuorescently-labeled polymer
For the preparation of ﬂuorescently tagged EAB, Cy3 NHS ester (GE
Healthcare, Piscataway,NJ) was coupled to EAB according to the
manufacturer's recommendations. 100 μg Cy3-labeled EAB that was
modiﬁed with PEG-FCit-PABC and NAG-ACit-PABC or PEG-FCit-PABC
alone was injected into the tail vein of mice. Liver tissues were harvest-
ed 6 h postinjection and preparation of tissue sections were performed
as previously described [14]. Tissue sections were counterstained with
Alexa-633-conjugated phalloidin (20 nM, Invitrogen, Carlsbad, CA)
and To-pro-3 (40 nM, Invitrogen) in PBS as previously described [14].
Mounted slides were analyzed using a Zeiss LSM710 confocal micro-
scope (Carl Zeiss Microimaging, Inc., Thornwood, NY).
2.13. Non-human primate study
Male cynomolgus monkeys were housed at the University of
Wisconsin–Madison. Prior to injection, animalswere sedatedwith keta-
mine (10 mg/kg, injected intramuscularly). DPC samples were injected
into the small saphenous vein slowly over 5 min at a volume of 2 mL/kg
or subcutaneously in between the shoulder blades over 5-10 s at a
volume of 0.1 mL/kg. Blood samples were collected every 3–4 days for
measurement of fVII activity and prothrombin time. All procedures
were carried out in accordance with the National Research Council's
Guide for the Care and Use of Laboratory Animals (National Research
Council [U.S.], 2011) and were approved by the University of
Wisconsin–Madison and Arrowhead Madison, Inc. animal care and
use committees.
2.14. Quantitative Real-Time PCR
In preparation for quantitative PCR, total RNA was isolated from tis-






Fig. 2. a) The structure of amphipathic delivery polycation based on co-polymerization of
ethoxyethylamine and isobutyl acrylates (EAB). The polymer is generated by random co-
polymerization of amine, which is protected with BOC groups during polymerization, and
alkyl monomers. b) The effective concentration of EAB required to attain 25% hemolysis
(EC25) as a function of modiﬁcation with PEG12.
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reverse-transcribed using the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems). Pre-manufactured TaqMan gene expres-
sion assays for mouse Factor VII (Assay ID: Mm00487333_m1) and ß-
actin (Part#: 4352341E) were used in biplex reactions in triplicate
using TaqMan Gene Expression Master Mix (Applied Biosystems).
Quantitative PCR was performed by using a 7500Fast or StepOnePlus
Real-Time PCR system (Applied Biosystems) and analyzed by the
ΔΔCT method to calculate relative gene expression.
2.15. Serum FVII activity measurements
Serum samples formmice were prepared by collecting blood (9 vol-
umes) by submandibular bleeding into microcentrifuge tubes contain-
ing 0.109 M sodium citrate anticoagulant (1 volume) following
standard procedures. FVII activity in serum is measured with a chromo-
genic method using a test kit (BIOPHEN VII, Aniara, Mason, OH) follow-
ing the manufacturer's recommendations. Absorbance of colorimetric
development was measured using a Tecan Saﬁre 2 microplate reader
at 405 nm.
2.16. Zeta and particle sizing
The size and surface potential of the siRNA-polymer conjugateswere
measured by light scattering using a Malvern, ZetaPlus Particle Sizer,
I90. Samples were analyzed at a polymer concentration of 5 mg/mL
polymer (0.5 mg/mL siRNA).
3. Results and discussion
There are three main components in a DPC siRNA delivery formula-
tion: siRNA, amembrane-interactive polymer, and an agent that revers-
ibly masks the membrane interactions of the polymer. A variety of
polymers have been studied as components in DPCs, but the common
design motif is amphipathicity. Hydrophilic character is derived from
primary amines, which serve as sites for reversible masking either by
pH-labile maleic anhydride groups [14] or the protease-labile groups
described in this study (Fig. 1). Polymers developed for pH-sensitive
DPCs have been demonstrated to deliver siRNA to the liver in vivo
when their amine groups were reversibly masked with pH-labile hepa-
tocyte targeting groups [14]. In this report, we examined reversible
masking of the same amphipathic polymers (R-NH2 in Fig. 1)with puta-
tive protease-labile hepatocyte targeting reagents for their ability to fa-
cilitate cytoplasmic access of siRNA.
The membrane interactive polymer used to test the reversibility of
protease-cleavable reagents for delivery of siRNA is an amphipathic
polyacrylate that is derived from copolymerization of ethoxyethylamine
and sec-butyl acrylate monomers to produce a polymer termed EAB
(Fig. 2a). Alkyl monomer sec-butyl acrylate (45 mol% of feed) and
amine monomer tert-butoxycarbonyl (2-aminoethoxy)ethyl acrylate
(55 mol% of feed) were copolymerized to generate an amphipathic
polymer. The amine monomer incorporates at a slightly faster rate,
which results in higher amine incorporation than the feed at an average
of 40 ± 5% butyl to 60 ± 5% amine. The chemical structure of EAB is
presented in Fig. 2a, but is represented in illustration Fig. 5 as a
green curve where amine side chains are represented as green
ovals and propyl side chains are gray ovals. In separate studies, EAB
and similar amphipathic polyacrylates were shown to be effective
components in DPC formulations when masked with pH-labile
modiﬁcations [15]. EAB was polymerized by controlled reversible
addition-fragmentation chain-transfer (RAFT) polymerization using
4-cyano-4-(phenylcarbonothioylthio) pentanoic acid (CPCPA) as a
RAFT agent. Polymers produced under RAFT conditions are synthe-
sized synchronously such that the resulting polymers are similar in
composition [16].The amphipathic polycation EAB interacts with negatively charged
membranes by electrostatic and hydrophobic interactions. A measure
of the membrane instability caused by these interactions is the amount
of hemoglobin released from red blood cells (RBCs) upon exposure to
membrane interactive agents [17,18]. EAB at 0.3 μg/mL concentration
results in 25% lysis of RBCs while EAB that has greater than N95% of
amine groupsmodiﬁed with PEG12-NHS ester has no observable hemo-
lytic activity up to practical limit of testing of 800 μg/mL, which is a
greater than 2500-fold reduction in the membrane lytic properties of
EAB (Fig. 2b). Even amoderate level of PEGmodiﬁcation results in a sig-
niﬁcant reduction in hemolytic activity as a 10% PEG modiﬁcation re-
sults in an 80-fold decrease in EC25 (from 0.3 to 25 μg/mL). These
results demonstrate both the membrane disruptive ability of EAB and
the effect of amine modiﬁcation to attenuate membrane disruption by
reduction of charge and increasing hydrophilic composition.
The key to functional in vivo delivery is to control polymer–
membrane interactions such that they are reduced until the desired
intracellular site of activation is desired. A particularly well-studied
protease-cleavable prodrug strategy uses the 1,6 elimination of a
p­aminobenzyloxycarboxyl (PABC) group to produce a traceless
linker to an amine-containing drug (Fig. 3). Upon proteolysis of
the anilide bond of amino acid (Aa) PABC derivative, there is an
elimination reaction to produce carbon dioxide, an amine, and an
azaquinonemethide, which then reacts with water to form p-
aminobenzyl alcohol [19]. These series of reactions result in the forma-
tion of an amine and an amino acid, just as produced in a standard pro-
teolytic reaction; however, the PABC group provides a spacer that
allows for proteolysis of non-peptidic amino substrates.
The widely-expressed lysosomal protease cathepsin B (catB) is a
commonly-invoked protease for the release of prodrugs, whose pre-
ferred substrates have a cationic residue (K or R) followed by a hydro-
phobic residue (F, V etc.) on the carboxy side of the hydrolyzed
peptide bond [20,21]. For example, the majority of the work presented
in this report uses the H2N-phenylalanine-citrulline-PABC-CO2H (FCit-
PABC) motif, where proteolysis is presumed to occur between citrulline
Fig. 3. The structure and cleavage of self-immolating linker based upon p-aminobenzyl alcohol.
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its neutrality is a particularly attractive amino acid residue for the pur-
poses of circulation and targeting in vivo [20–22].
In DPC formulations, the membrane interactive polymer is revers-
ibly masked with a mixture of polyethylene glycol (PEG) and cell-
targeting ligands [14]. PEG groups reduce non-speciﬁc interactions
and prevent the aggregation of the nucleic acid delivery vehicles. Cell-
speciﬁc targeting to hepatocytes is accomplished by modiﬁcation ofFig. 4. Reagents used for the modiﬁcation of polyamine: protease-cleavable reversible masking
acetylgalactosamine (NAG) reagent based upon disubstituted maleic anhydride (CDM-NAG).the delivery vehicle with N-acetylgalactosamine (NAG), which is a li-
gand for the asialoglycoprotein receptor on hepatocytes [23].
Attachment of PEG groups to a polymer decreases non-speciﬁc inter-
actions in vivo [24]; however, permanent PEG masking of N10% of
polymer amines completely inhibits intracellular delivery ability of
pH-labile DPC formulations (vide infra). For this reason, the ability of a
partially PEGylated polymer to deliver functional siRNA is an indirect as-
sessment of the reversibility of the PEGmodiﬁcation: i.e. only reversiblereagents based upon p-aminobenzyl carbonate (PABC derivatives) and pH reversible N-
Fig. 5. Illustration of DPCwhere polymer EAB (green curvewith amine side chains represented as green ovals and alkyl groups that are denoted as gray ovals). The amine side chains of EAB
are modiﬁed with PEG (gray squiggles) or hepatocyte-targeting NAG groups (orange circles) via pH or protease-labile bonds (blue circles). siRNA is attached to the polymer via disulﬁde
bonds (two purple circles). The placement of the disulﬁde bonds is randomly placed on polymer amine side chains, and not on the end of the polymer as represented.
Fig. 6. fVII activity (left axis, black bars) andmRNAquantitation (right axis, gray bars) after
intravenous administration of DPC formulations masked with a mixture of pH-labile
(CDM-NAG) and protease-labile modiﬁcations. Formulations were injected via tail vein
in mice (n= 4). Samples were taken 7 days postinjection. fVII activities and mRNA levels
were normalized to mice treated with isotonic glucose.
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attached PEG completely inhibits the delivery of functional siRNA.
To simplify synthesis and screening of amino acid-basedmasking re-
agents, relatively easy to synthesize (PEG) derivatives were initially
evaluated. PEG reagents were composed of a discrete 12-mer of PEG
and naturally occurring L enantiomers of the amino acid sequence
phenylalanine-citrulline (FCit). The PEGmasking reagents were activat-
ed for reaction with amine groups as p-nitrophenol carbonate esters,
which react with amine groups to form a carbamate bond (PEG-FCit-
PABC).
PEG-modiﬁed delivery vehicles are not selectively targeted to any
tissues in vivo and require masking with a targeting ligand. Functional
delivery of siRNA also requires that the targeting group not inhibit inter-
action between the delivery polymer and the endosomal membrane.
Unfortunately, the valency and hydrophilicity of NAG targeting reduce
polymer–membrane interactions. Therefore, NAG attachment to a DPC
polymer must be reversible for the functional delivery of siRNA. As an
initial test of protease-labile PEG reagents, hepatocyte targeting is
accomplished by reversible modiﬁcation with pH-labile CDM-NAG
(Fig. 4), which reversibly modiﬁed polyamines with NAG via a pH-
labilemaleamate group [14]. This pH-labile NAG reagent in combination
with PEG reagents whose reversibilities are under evaluation enables
testing of the new reversible chemistries without synthesis of relatively
complicated N-acetylgalactosamine derivatives. The chemical struc-
tures of reagents synthesized for the modiﬁcation of polyamine EAB
are presented in Fig. 4, but are also represented schematically in Fig. 5
where PEG is gray squiggle and NAG is an orange circle. The labile
bonds (either protease-labile PABC or pH-labile maleamate bonds) are
represented as blue circles.
The formulation of DPC delivery vehicles was a four-step process. At
each step the four components of a hepatocyte-targeted DPC are intro-
duced: polymer, PEG, siRNA and NAG. First, the polymer was modiﬁed
with a pyridyl disulﬁde group using a commercially-available amine-
reactive reagent. Second, the polymer was modiﬁed with 0.25 mol
equivalents of PEG reagent per mole of amine in the polymer. This
PEG to amine stoichiometry resulted in PEG attachment to 20–25% of
the polymer amines, which is measured by the reduction in amine con-
tent as measured by colorimetric assay using trinitrobenzenesulfonic
acid (TNBS). This extent of PEG modiﬁcation is enough to inhibit the
membranolytic activity of the formulation (Fig. 2a and delivery results
to follow in Fig. 6), but not extensive enough to signiﬁcantly inhibit
the electrostatic interactions between the cationic polymer and anionic
nucleic acids.
Third, thioacetyl-modiﬁed siRNA [14] against the endogenous,
hepatocyte-expressed blood clotting factor VII (fVII) was added to the
formulation. Chemical modiﬁcation of siRNAs provides protection
from rapid degradation in serum by ribonucleases [25] and preventscytokine induction [26]. For these reasons, the riboses of the siRNA
used in this study were modiﬁed at the 2′ position with a mixture of
methoxy and ﬂuoro groups. As a measurement of functional knock-
down, siRNA targeting coagulation Factor 7 (FVII) was used. FVII is
expressed exclusively in hepatocytes and secreted into the bloodstream.
The level of FVII activity in plasma is easily monitored by a simple chro-
mogenic assay. To test for any potential vehicle-related knockdown, for-
mulations were also made using siRNAs designed for the exogenous
ﬁreﬂy luciferase gene.
The anionic siRNA and cationic partially PEGylated polymer form an
electrostatic complex. In order to prevent aggregationduring the siRNA-
polymer conjugation reaction, one of the components of the polyelec-
trolyte complex (either siRNA or polymer) must be in excess. As a prac-
tical matter, the relatively inexpensive reagent (polymer) is added in
excess. For data presented in this report, the polymer to siRNA is a
10:1 weight ratio (3:1 molar ratio). The electrostatic complex between
polymer and siRNA accelerates the reaction between nucleophilic
amine groups of the polymer and electrophilic thioacetyl group of the
siRNA, which results in the acetylation of one polymer amine and the
formation of a thiol on siRNA. The siRNA thiol may then react with the
pyridyl disulﬁde on the polymer resulting in a siRNA-polymer conjuga-
tion via a disulﬁde bond [14]. The resulting disulﬁde bond between EAB
and siRNA is represented in Fig. 5 as two purple circles.
The efﬁciency of conjugation of siRNA and polymer was calculated
from the ratio of unconjugated siRNA in formulations to the amount of
free siRNA after reduction with dithiothreitol. Quantitation of free
siRNA was performed using agarose gel electrophoresis and staining
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80–90% for formulations presented in this report (Table 1).
Once polymer and siRNA were conjugated, the polymer-siRNA con-
jugate was exhaustively modiﬁed with 2 mol equivalents of maleic an-
hydride derivative CDM-NAG (Fig. 4) per polymer amine, which reacts
with the remaining 50% of the polymer amines. The result is a masked,
hepatocyte-targeted siRNA-polymer conjugate (DPC). The degree of
polymer modiﬁcation after the addition of excess of maleic anhydride
is extensive enough (N95% of available amines) such that there is little
if any electrostatic interaction between polymer and siRNA, and there
would be no co-targeting of siRNA and polymer without covalent at-
tachment of siRNA to polymer [14,27]. The resulting NAG-modiﬁed
polymer-sRNA conjugate (illustrated in Fig. 5) is ready for injection.
The formulated vehicles were then injected into the tail vein of mice
(20 μg of siRNA conjugated to 200 μg of polymer in 200 μL volume).
Serum and liver tissue were collected one week after tail vein injection.
The enzymatic activity of the FVII proteasewasmeasured in plasma, and
the amount of FVII transcript was quantiﬁed using real-time PCR after
mRNA was extracted from liver tissue. The results in Fig. 6 showed
that protease cleavable PEG-modiﬁed DPC achieved a 79% knockdown
in serum FVII activity (left axis, dark bars) and a corresponding 62%
knockdown in FVII mRNA (right axis, light bars).
No FVII knockdown, relative to injection of isotonic glucose, was ob-
served with a DPC containing a non-coding siRNA indicating that FVII
knockdownwas sequence speciﬁc, consistentwith anRNAimechanism.
To demonstrate that irreversible PEG modiﬁcation is truly inhibitory of
functional delivery, formulations were permanently PEGmodiﬁed with
a commercially-available PEG12 NHS ester. Consistent with protease-
mediated unmasking, the formulation with a non-cleavable PEG did
not result in knockdown. The only formulation that resulted in knock-
down of fVII activity and mRNA levels contained protease-cleavable
PEG and the appropriate siRNA.
Further evidence for proteolytic processing of PEG-FCit-PABC modi-
ﬁed polymers was observed upon incubation of masked polymer in the
presence of rat livermicrosomal proteases. It is difﬁcult to interpret EAB
molecular weights by size exclusion retention times due to the
amphipathic nature and cationic charge of the polymer, which
cause retention time changes independent of molecular weight. For
this reason, a reagent was prepared that linked the chromophore p-
nitrophenylethylenediamine (PNPEDA) to EAB via an ACit-PABC
bond (see supplemental section for description). The incubation of
polymer modiﬁed with PNPEDA-ACit-PABC with rat lysosomal ex-
tract produced a small molecule chromophore with an approximate
half-life of 1 h (see supplemental Fig. 6), which provides an estimate
of the lability of ACit-PABC and is consistent with cleavage of
citrulline-PABC amide bond by lysosomal proteases.
In addition to the FCit motif, a variety of peptide sequences com-
posed of 1–2 residues with various charged and uncharged residues
were tested (see Fig. 1 of supplementary data). The modiﬁcation of
the delivery polymer with a variety of dipeptide motifs allows for func-
tional delivery. This limited data set is consistent with the cathepsin
motif of a hydrophobic (F, V, A) residue followed by a polar residueTable 1
Physical characteristics of protease-sensitive delivery vehicles.
Attribute Value
Molecular weight of EAB 50,000
Polymer charge density (MW/charge) 150/+




PEG:NAG ratio (mol:mol) 1:3
siRNA conjugation efﬁciency 90%
Molecular weight of vehicle (polymer + siRNA + masking groups) 225,000
a Calculations for 10:1 weight ratio polymer to siRNA formulated vehicle.(Cit, dimethyl-K, N) as good substrates for unmasking. The only
naturally-occurring L amino acid-based modiﬁcations that appear to
drastically reduce delivery are the modiﬁcations with only one amino
acid, which suggests that single amino acid derivatives are relatively
poor substrates for proteolysis.
Functional delivery using a mixture of protease-labile PEG reagents
and pH-labile targeting reagents was a relatively facile demonstration
of the potential of using protease substrates in delivery vehicles. In
order to produce targeted delivery vehicles that rely solely on proteases
for unmasking and delivery, PBAC reagents containing a hepatocyte-
targeting NAG ligand were synthesized (Fig. 4). Initially, NAG-
containing reagents using the FCit dipeptide motif were synthesized;
however, formulations of polymersmodiﬁedwith NAG-FCit had limited
solubility and were prone to gel or form viscous solutions. To circum-
vent this propensity, NAG-containing reagents using the more water-
soluble dipeptide alanine-citrulline (ACit) motif were synthesized
(Fig. 4, NAG-ACit-PABC). To test the stereospeciﬁcity of peptide cleav-
age, reagents composed of non-natural D enantiomers of phenylalanine,
alanine and citrulline were also synthesized (fcit and acit).
siRNA delivery DPCs composed of polyacrylate EAB modiﬁed with
PEG-FCit and NAG-ACit were formulated as before where PEG reagents
were screened except the putative protease cleavable NAG reagent
NAG-ACit-PABC was used instead of pH-labile CDM-NAG. One formula-
tion (non-targeted group in Fig. 7) was not treated with NAG reagent,
but was extensively modiﬁed with a second addition of PEG-FCit-PABC.
Formulations of polymer-conjugated FVII siRNA, which were modi-
ﬁed with protease cleavable PEG and NAG were injected into mice via
tail vein (n = 5, 20 μg of siRNA conjugated to 200 μg of polymer in
200 μL volume). Serum and liver tissue samples were collected 7 days
after injection and assayed for fVII enzyme activity and FVII mRNA ex-
pression. The results presented in Fig. 7 demonstrate functional delivery
of siRNA based solely on enzymatic unmasking of the membrane inter-
active polymer. Both FVIImRNA and enzyme levels were decreased 75%
after a single injection of 0.25 mg/kg siRNA formulated with 2.5 mg/kg
of masked polymer. Consistent with an enzymatic process, functional
delivery is stereospeciﬁc as formulations modiﬁed with reagents con-
taining D enantiomer amino acids were not functional in vivo.
No knockdown was observed in DPC formulations where only PEG
masking reagents were used (non-targeted group in Fig. 7). The
in vivo dispositions of NAG-targeted and PEG-only formulations were
studied using radiolabeled polymer. The NAG-modiﬁed formulation ac-
cumulated rapidly in the liver, with 80% of dose associatedwith the liver
1 h postinjection. The PEG-only formulation had a relatively low (b10%)
and constant amount associated with the liver (see supplemental
Fig. 5). The PEG-only formulation circulates relatively long term with a
half-life of circulation of 11 h (see Fig. 5a of supplemental). While the
PEG-only formulation does not target any tissue selectively, the serumFig. 7. fVII activity (left axis, black bars) andmRNAquantitation (right axis, gray bars) after
intravenous administration of DPC formulations modiﬁed solely with protease-labile
modiﬁcations. Formulations were injected via tail vein in mice (n = 4). Samples were
taken 7 days postinjection. fVII activities andmRNA levels were normalized tomice treat-
ed with isotonic glucose.
Fig. 9. fVII activity (left axis, black bars) andmRNAquantitation (right axis, gray bars) after
intravenous administration of DPC formulations of various siRNAand polymer doses using
a ﬁxed siRNA:polymer weight ratio of 10:1. Formulations were injected via tail vein in
mice (n = 4). Samples were taken 7 days postinjection. fVII activities and mRNA levels
were normalized to mice treated with isotonic glucose.
64 D.B. Rozema et al. / Journal of Controlled Release 209 (2015) 57–66circulation time suggests that the vehicles are stable and relatively non-
interactive with components such as the extracellular matrix or cellular
membranes that would prevent circulation.
The liver-associated material for targeted and untargeted formula-
tions was evaluated using confocal microscopy. As can be seen from
Fig. 8A, theNAG-modiﬁed formulation accumulates preferentially in he-
patocytes (cells containing larger nuclei). While not quantitative, the
PEG-modiﬁed material was less intense and not hepatocyte-speciﬁc
(Fig. 8B).
To determine the efﬁcacy of a 10:1 polymer:siRNA weight ratio for-
mulation, a dose titration study was performed and is presented in
Fig. 9. The dose required to reduce FVII enzymatic activity by 50% rela-
tive to untreated animals is roughly 1.25mg/kgwith respect to polymer
and 0.125 with respect to siRNA.
In the studies described in Figs. 6–7 and 9, the polymer to siRNA ratio
was held at 10:1 ratio, but different ratios were used. To test whether
siRNA or polymer was limiting at the ED50 observed in Fig. 9
(1.25 mg/kg polymer with 0.125 mg/kg siRNA), a study was performed
where the dose of polymer was held constant at 1.25 mg/kg and the
siRNA dose was increased to 0.25 mg/kg. This increase in siRNA dose
changed the molar ratio from 3:1 to 1.5:1 polymer to siRNA. No further
increase in knockdown was observed at this increased siRNA dose,
which suggests that the ED50 of 1.25 mg/kg polymer at 10 to 1 poly-
mer:siRNA ratio is due to a lack of delivery polymer and not siRNA.
See Fig. 3 of supplementary data section for dose titration of siRNA at
constant 1.25 mg/kg polymer dose.
The presumed mechanism of endosomal lysis, which leads to cyto-
plasmic access of the siRNA, relies upon increased polymer–membrane
interactions as masking groups are removed and the neutral polymer
becomes positively charged. The observation that the ED50 with respect
to polymer is equivalent at 3 and 1.5 to 1 polymer to siRNAmolar ratios
suggests that themechanism of delivery requiresmultiple polymers (or
interactions between polymers) to affect cytoplasmic delivery of siRNA,
and that multiple polymers may need to be in the same intracellular
compartment in order for the polymers to increase membrane
permeability.
Maximum knockdown was observed 7 days after injection (A time
course of fVII activity is presented in Fig. 2 of supplementary data.).
The fact that mRNA reduction and presumably access to the cytoplasm
require days during which the siRNA is exposed to nucleases suggests
that the siRNA is protected from nucleases during the time between in-
jection and its cytoplasmic entry and incorporation into the RNA-
induced silencing complex. The research presented in this report does
not address the source of siRNA stability, but some of the protection of
the oligonucleotide undoubtedly comes from the 2′ modiﬁcationsFig. 8.Confocalmicrographs of Cy3-labeled EAB inmouse liver sections. Confocal images of Cy3-
harvested,ﬁxed, and counterstainedwith To-Pro-3 to visualize nuclei (blue) and Alexa-633 pha
optical images (0.4 mm each) to represent combined ﬂuorescence signals from a 4-mm-thick[28], while further nuclease resistancemay be derived from covalent at-
tachment to masked polymer, which is becoming positively charged
and hence nuclease protective upon proteolysis in the endosomes/
lysosomes.
For all of themasking reagents tested, the resulting formulations are
small (20 nm) and have a negative surface charge (−10 mV ζ-
potential) due to the presence of the anionic siRNA (Table 1). In addi-
tion, the delivery vehicles are stable and nonaggregating, which enables
puriﬁcation and long-term storage. These attributes suggest that these
formulations would be amenable to subcutaneous injections, which re-
quire stability in the lymphatic system before accessing the vasculature.
Indeed, injection of FCit-PABCmodiﬁed EAB-siRNA conjugates (5mg/kg
EAB and 0.5 mg/kg siRNA) results in greater than 80% knockdown of
FVII 7 days after subcutaneous injection in mice (data not shown).
A comparison of subcutaneously and intravenously administered
protease-labile DPCs in primates is presented in Fig. 10. To minimize
any potential toxicity from p-nitrophenol (PNP), which is generated
upon reaction of polymer amine with PNP-activated carbonate, the for-
mulations were puriﬁed by ultraﬁltration to remove small molecules
such as PNP and any unconjugated PEG or NAG reagents. In order to de-
crease the volume of injection, the puriﬁed formulations were lyophi-
lized and reconstituted in isotonic glucose at 200 mg/mL of polymer
(20 mg/mL siRNA). The puriﬁed, concentrated formulations were
injected at 5 mg/kg EAB polymer formulated with 0.5 mg/kg siRNA
against primate fVII either intravenously or subcutaneously intolabeled EABmodiﬁedwith NAG/PEG (A) or PEG alone (B) using PABC reagents. Liverswere
lloidin to visualize cell outlines (green). Each image comprised a ﬂattened projection of 11
section.
Fig. 10. fVII activity after intravenous or subcutaneous administration of DPCs at 5 mg/kg
polymer in non-human primates (N = 2). Serum fVII activities were normalized to
preinjection levels in non-human primate after intravenous and subcutaneous adminis-
trations. Lines represent individual animals and symbols (squares and circles) represent
the average of both animals at each time point. Solid lines and ﬁlled circles are data for
subcutaneous administration. Dashed lines and open squares are data for intravenous ad-
ministration of DPC formulation.
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tion, plasma sampleswere collected. For either routes of administration,
a 99% reduction of FVII was observed.
Maximal knockdown in primates was measured 10 days postinjec-
tion for intravenous injection and 24 days for subcutaneous injection.
The difference in knockdown kinetics between the routes of administra-
tion suggests that the subcutaneously injected formulation is delayed in
the lymphatic system before arrival in the liver. A prolonged duration of
knockdownwas observedwithmeasurable reduction in FVII activity up
to 200 days after a single injection of siRNA. The prothrombin time (PT),
which is the amount of time for plasma to clot after the addition of tis-
sue factor, was also measured. Blood clotting kinetics are a function of
FVII levels, and an expected phenotypic increase in PT was observed
as fVII levels decreased (see Fig. 4 of supplementary data).
4. Conclusion
A new class of siRNA delivery vehicles that are dependent upon in-
tracellular protease activity has been developed. These delivery vehicles
are based upon a general strategy where membrane interactive poly-
mers are reversibly masked to inhibit membrane interactions. The key
to functional delivery is control of the unmasking reaction such that it
occurs selectively after internalization. The masking chemistry de-
scribed is reversed by proteolysis of peptide linkages between hydro-
philic groups and membrane interactive polymers. The hydrophilic
groups may be PEG, which prevent nonspeciﬁc interactions, and/or
cell-speciﬁc targeting groups such as NAG,which target the formulation
to hepatocytes. Consistent with the enzymatic control of delivery, the
unmasking is substrate speciﬁc as reagents containing non-natural D
enantiomer amino acids do not allow for functional delivery of siRNA
in vivo.
While observations such as the attenuation of hemolysis after PEG
modiﬁcation (Fig. 2b) and the dependence of functional siRNA delivery
on modiﬁcation via L amino acids (Fig. 7) are consistent with designed
mechanism of delivery, the exact intracellular events such as the extent
of unmasking required for delivery and the extent of the endo/lysosom-
almembrane disruptionwhereby themodiﬁed polymers provide access
of the siRNA to cytoplasm are outside the scope of the work presented.
Presumably, EAB after extensive proteolytic removal of hydrophilic PEG
and NAG produces — like other amphipathic polycations [17] —
nanometer-sized holes in membranes, which causes inﬂux of small
molecules and ultimately membrane disruption via a colloid-osmotic
mechanism of lysis.
The protease-masked delivery vehicles are small and non-
aggregating. The stability of the DPC masking chemistry in the absenceof proteases ensures that the vehicles stay intact and not positively-
charged until they reach their intended intracellular target. In addition,
the covalent attachment of siRNA and polymer prevents displacement
of siRNA from the delivery polymer. These attributes enable the transit
of the siRNA and its DPC delivery vehicle in the lymphatic and vascula-
ture systems before reaching the target liver tissue.
In addition to the stability required for functional delivery after sub-
cutaneous delivery, there are no observed changes in physical properties
(Table 1) or in vivo efﬁcacy after storage for at least a year as either a ly-
ophilized solid or in solution, which will aid in the manufacturing and
analytics of therapeutics based upon protease masking.
The liver, due to its unique vasculature structure, is relatively easy to
access. In order to deliver to relatively less accessible tissues such as tu-
mors, formulations must be small and long-circulating in order for ex-
travasation to occur. The in vitro stability and the in vivo stability
required for subcutaneous administration of protease-dependent DPCs
are consistent with the requirements needed for extrahepatic targeting
where extravasation is not as facile as for the liver. Tissue-selective
targeting also requires ligand-mediated delivery. Functional delivery
of siRNA by DPCs to hepatocytes is dependent on the NAG targeting li-
gand, which suggests that protease sensitive DPCs can — with the at-
tachment of appropriate targeting ligands — be actively targeted to
other tissues. For these reasons (size, stability and targetability),
protease-sensitive delivery vehicles are a potentially attractive strategy
for extrahepatic delivery.
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